novartis heart drug entresto gets ema nod for expanded use in children.

novartis gets positive chmp opinion for entresto for pediatric heart failure. (rttnews) - novartis ag (nvs) announced friday that the european medicines agencys (ema) committee for medicinal products for human use (chmp) has adopted a positive o

why novartis (nvs) is a great dividend stock right now. all investors love getting big returns from their portfolio whether its through stocks bonds etfs or other types of securities. however when youre an income investor your primary

bicycle (bcyc) up on collaboration with novartis for conjugates. bicycle therapeuticsbcyc announced that it entered into a strategic collaboration agreement with swiss pharma bigwig novartis nvs to develop manufacture and commercialize

bicycle stock pops on cancer drug discovery pact with novartis gets $50m upfront.

novartis (nvs) kisqali positive for early breast cancer. novartis ag nvs announces positive top-line results from an interim analysis of late-stage natalee study on breast cancer drug kisqali.natalee is a global phase iii multi-center

nvs makes ish cross above critical moving average. in trading on monday shares of novartis (symbol: nvs) crossed above their 200 day moving average of $84.53 changing hands as high as $89.81 per share. novartis shares are currently trading

why novartis shares are trading higher premarket today. ) shares are trading higher in the premarket session after its breast cancer drug showed clinical benefit in early-stage breast cancer. novartis announced topline

novartis stock jumps on cancer trial success.

novartis : phase iii trial of kisqali combination in early breast cancer meets primary endpoint. (rttnews) - novartis (nvs) announced positive results from an interim analysis of natalee a phase iii trial evaluating kisqali (ribociclib) plus end

novartis humira biosimilars high concentration gets fda approval.

sandoz gets fda approval for biosimilar hyrimoz high-concentration formulation. (rttnews) - sandoz a novartis (nvs) division said tuesday that that the us food and drug administration approved a citrate-free high-concentration formulation (hcf)

novartis reveals long-term data of atrophy gene therapy exhibiting sustained durability of up to 7.5 years.

novartis (nvs) oncology drug gets fda nod for label expansion. novartis nvs announced that the fda granted approval to the combination of tafinlar (dabrafenib) and mekinist (trametinib) for another indication.

novartis tafinlar mekinist combo gets fda approval to treat brain cancer in children.

fda approves novartis tafinlar mekinist for pediatric brain cancer with certain mutations. the fda has

novartis prostate cancer therapy hit by supply crunch seeks to ramp up production to ease supply issues. last week the fda said) pluvicto is short in supply due to manufacturing and delivery issues. pluvicto is a radiopharmaceutical medication used for

shortage of last-ditch drug for advanced prostate cancer worries doctors. novartis seeks to ramp up production of the drug pluvicto to ease supply issues.

novartis (nvs) could be a great choice. whether its through stocks bonds etfs or other types of securities all investors love seeing their portfolios score big returns. but for income investors generating consistent cash flow from each

novartis initiates new trading line for share buybacks.

novartis launches chf10b stock buyback program.

novartis sandoz to invest $400m to build biosimilar production plant in slovenia.

sandoz recalls aprepitant capsules lidocaine and prilocaine cream. (rttnews) - sandoz the generics and biosimilars division of swiss drug major novartis ag is recalling about 156750 units of aprepitant capsules and lidocaine and prilocaine cream

heres why novartis (nvs) is a strong value stock. for new and old investors taking full advantage of the stock market and investing with confidence are common goals. zacks premium provides lots of different ways to do both.

novartis sandoz signs mou to build biologics production plant in lendava slovenia. (rttnews) - novartis ags (nvs) generics-and-biosimilars division sandoz signed a memorandum of understanding to build a new biologics production plant in lendava

voyager stock pops on getting $25m from novartis under license deal.

novartis files for fda approval of radioligand facility to ramp up production of pluvicto.

after plunging -7.17% in 4 weeks heres why the trend might reverse for novartis (nvs). novartis (nvs) has been on a downward spiral lately with significant selling pressure. after declining 7.2% over the past four weeks the stock looks

novartis becomes oversold (nvs). legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful. one way we can try to measure the level of fear in a given stock is through a technical a

novartis takes down $80m nash pact with pliant therapeutics. ) has decided to terminate the collaboration and license agreement with) announced in